- Home
- UNCY vs ENTX Comparison
UNCY vs ENTX Comparison
Compare UNCY & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- ENTX
- Stock Information
- Founded
- UNCY 2016
- ENTX 2010
- Country
- UNCY United States
- ENTX Israel
- Employees
- UNCY N/A
- ENTX N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UNCY Health Care
- ENTX Health Care
- Exchange
- UNCY Nasdaq
- ENTX Nasdaq
- Market Cap
- UNCY 74.2M
- ENTX 82.2M
- IPO Year
- UNCY 2021
- ENTX 2018
- Fundamental
- Price
- UNCY $4.63
- ENTX $1.91
- Analyst Decision
- UNCY Strong Buy
- ENTX Strong Buy
- Analyst Count
- UNCY 5
- ENTX 1
- Target Price
- UNCY $55.20
- ENTX $10.00
- AVG Volume (30 Days)
- UNCY 510.5K
- ENTX 50.8K
- Earning Date
- UNCY 11-12-2025
- ENTX 11-07-2025
- Dividend Yield
- UNCY N/A
- ENTX N/A
- EPS Growth
- UNCY N/A
- ENTX N/A
- EPS
- UNCY N/A
- ENTX N/A
- Revenue
- UNCY N/A
- ENTX $166,000.00
- Revenue This Year
- UNCY N/A
- ENTX N/A
- Revenue Next Year
- UNCY $4,481.14
- ENTX N/A
- P/E Ratio
- UNCY N/A
- ENTX N/A
- Revenue Growth
- UNCY N/A
- ENTX 191.23
- 52 Week Low
- UNCY $3.40
- ENTX $1.50
- 52 Week High
- UNCY $11.00
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- UNCY 61.71
- ENTX 53.16
- Support Level
- UNCY $3.72
- ENTX $1.84
- Resistance Level
- UNCY $4.80
- ENTX $1.93
- Average True Range (ATR)
- UNCY 0.24
- ENTX 0.08
- MACD
- UNCY 0.07
- ENTX 0.01
- Stochastic Oscillator
- UNCY 75.00
- ENTX 68.18
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.